MyMD Pharmaceuticals (MYMD) said Monday it has rebranded to TNF Pharmaceuticals to reflect its focus on targeting TNF-alpha for immune and metabolic system regulation.
TNF's stock will begin trading under the new Nasdaq Capital Market symbol "TNFA" before the market opens on Wednesday.
The drugmaker said it plans to advance its clinical development of TNF-alpha inhibitor drug MYMD-1 in sarcopenia, an age-related loss of muscle mass and strength, into mid-stage trials.
Shares of the company were up 1.2% in recent Monday trading.
Price: 1.80, Change: +0.02, Percent Change: +1.18
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。